Featured Content

Explaining Androgen Receptor-indifferent Prostate Cancer

Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.

Prostate Cancer: In Search of Predictive Biomarkers for Immunotherapy

Scientists are testing immune checkpoint proteins, CD8 T cell clonal expansion, mutational load, and PSA levels as predictive biomarkers for prostate cancer immunotherapy outcomes.

PSA Nadir Identifies High-risk Cases of Localized Prostate Cancer

PSA nadir greater than 0.5 ng/mL may serve as a surrogate marker to identify men with localized prostate cancer at high risk of mortality.

Prostate Cancer: Future of Research and Treatment

Recent discoveries of germline mutations are driving research in novel treatments, including immunotherapies, for prostate cancer.

Radiogenomics: Biomarkers for Prostate Cancer Radiotherapy Outcomes

Researchers are making progress in the search for biomarkers that can help identify which patients are most likely to benefit from radiotherapy.

Video Series

Prostate Cancer Resources

Special Edition Issue

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters